Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients | Zendy

Kohei Kushiro | Zendy; Satoshi Watanabe | Zendy; Yuka Goto | Zendy; Toshiya Fujisaki | Zendy; Naohiro Yanagimura | Zendy; Aya Ohtsubo | Zendy; Satoshi Shoji | Zendy; Koichiro Nozaki | Zendy; Tomohiro Tanaka | Zendy; Yu Saida | Zendy; Yusuke Sato | Zendy; Takeshi Ota | Zendy; Jun Koshio | Zendy; Yoshiki Hayashi | Zendy; Takao Miyabayashi | Zendy; Naoya Matsumoto | Zendy; Kosuke Ichikawa | Zendy; K. Koyama | Zendy; Toshiaki Kikuchi | Zendy

AI Assistant Blog Pricing

Open Access

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

Author(s) -

Kohei Kushiro,

Satoshi Watanabe,

Yuka Goto,

Toshiya Fujisaki,

Naohiro Yanagimura,

Aya Ohtsubo,

Satoshi Shoji,

Koichiro Nozaki,

Tomohiro Tanaka,

Yu Saida,

Yusuke Sato,

Takeshi Ota,

Jun Koshio,

Yoshiki Hayashi,

Takao Miyabayashi,

Naoya Matsumoto,

Kosuke Ichikawa,

K. Koyama,

Toshiaki Kikuchi

Publication year - 2022

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr-22-225

Subject(s) - medicine , chemoimmunotherapy , neutropenia , adverse effect , lung cancer , oncology , chemotherapy , retrospective cohort study , refractory (planetary science) , febrile neutropenia , surgery , cyclophosphamide , astrobiology , physics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog